Overview

• The Series says FDA‑approved antibodies lecanemab and donanemab mark a new era and can slow Alzheimer’s progression, though trial gains in symptoms were modest.
• The papers note safety concerns such as brain bleeding and inflammation, reinforcing the need for careful monitoring and informed use.
• Authors compare the therapies’ disease‑slowing effect to some medicines used in cancer, rheumatoid arthritis and multiple sclerosis, while cautioning that contexts and outcomes differ.
• Accessible blood biomarkers, already available in some countries, are expected to drive a diagnostic shift and require expanded imaging, laboratory capacity and trained clinicians.
• The experts call for coordinated global reforms across healthcare, policy and society, including stronger behavioral care and population prevention measures such as healthier urban design and curbs on alcohol and sugary drinks.